<?xml version="1.0" encoding="UTF-8"?>
<p>It is critical to understand EV-A71 disease burden for formulating national vaccination policy. Currently, national studies estimating EV-A71-related disease burden have been conducted in China [
 <xref rid="pntd.0008124.ref031" ref-type="bibr">31</xref>] and Taiwan [
 <xref rid="pntd.0008124.ref032" ref-type="bibr">32</xref>]. A similar study was recently conducted in southern Vietnam and found that a total cost of more than 90 million USD was caused by HFMD during 2016â€“2017, and the cost attributed to EV-A71 was much higher than that caused by other EV serotypes [
 <xref rid="pntd.0008124.ref033" ref-type="bibr">33</xref>]. Moreover, harmonized laboratory-based enterovirus surveillance system is not available globally and it is urgently needed in Asian countries experiencing large-scale EV-A71 epidemics.
</p>
